leadf
logo-loader
viewPrescient Therapeutics Ltd

Prescient Therapeutics has path forward as they look to future of cancer treatments

Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive to share details about the company that is personalizing cancer treatment using CAR-T cell therapy.

Yatomi -Clarke telling Proactive about their work and also some recent big news for the company including being issued two U.S. patents.

Quick facts: Prescient Therapeutics Ltd

Price: 0.069 AUD

ASX:PTX
Market: ASX
Market Cap: $44.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Cabral Gold identifies new high-grade zone north of Medusa at Cuiu Cuiu...

Cabral Gold (CVER: CBR-OTC: CBGZF) CEO Alan Carter joined Steve Darling from Proactive with news drilling on the Cuiu Cuiu projects has turned up another high-grade zone. Carter telling Proactive about this new zone located North of the Medusa Target. He also told Proactive about a new drill...

32 minutes ago

2 min read